stockrow
Friday 6 November 2026
Export TENX’s income statement to Excel — free account
Tenax Therapeutics, Inc.
TENX Healthcare Biotechnology
- EPS
- −29.6%
- Free cash flow
- −125.9%
Quarter to June 2026, against a year earlier
1.64
0.17
−9.39%
Follow TENX
Alert me
Tenax Therapeutics, Inc. (TENX) P/E ratio
Tenax Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2015 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CNXU Conexeu Sciences Inc. compare | n/m |
| CRDF Cardiff Oncology, Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | n/m |
| CSBR Champions Oncology, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)